With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug
Up next
Author


The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.

You May Also Like
Libya’s oil output ‘cannot be easily replaced,’ analysts warn

Libya’s oil output ‘cannot be easily replaced,’ analysts warn

The oil market’s attention was turning to North Africa on Monday, with…
Regional-bank stocks are hot, and this PNC purchase suggests the rally can continue

Regional-bank stocks are hot, and this PNC purchase suggests the rally can continue

PNC is making its largest acquisition in four years as one dealmaker…
Some retirees like to be alone — is that a bad thing?

Some retirees like to be alone — is that a bad thing?

Is flying solo bad for your health?

Olympics chiefs blame ‘misleading information’ for women’s boxing row

The International Olympic Committee has defended its decision to allow two boxers…